Curated News
By: NewsRamp Editorial Staff
August 13, 2024

PathAI Launches AI-Based Measurement of Metabolic Dysfunction-Associated Steatohepatitis (AIM-MASH) on AISight IMS

Reddit Discuss on RedditDiscuss on Substack Discuss on Substack
Source News Release

TLDR

  • PathAI's AIM-MASH on AISight increases reproducibility and scalability for pathologists, providing an advantage in making high-quality, reproducible MASH assessments.
  • AIM-MASH uses AI-based measurement tools to support the analysis of MASH CRN MASLD activity score component grades and fibrosis staging.
  • AIM-MASH on AISight aims to make the world a better place by providing digital and AI tools to assist pathologists in making precise and reproducible assessments at scale.
  • AIM-MASH provides advanced AI-based measurement to support the analysis of MASH CRN MASLD activity score component grades and fibrosis staging.

Impact - Why it Matters

This news matters as it introduces a groundbreaking AI-based measurement tool, AIM-MASH, to support pathologists in making high-quality, reproducible MASH assessments. The launch of AIM-MASH on AISight IMS addresses a crucial gap in pathology labs, providing digital and AI tools to assist pathologists in making precise and reproducible assessments at scale, ultimately impacting the accuracy and efficiency of MASH evaluations.

Summary

PathAI, a global leader in artificial intelligence (AI) and digital pathology solutions, has launched its AIM-MASH1 product on the AISightⓇ1 Image Management System (IMS). This product provides advanced AI-based measurement (AIM) to support the analysis of MASH Clinical Research Network (CRN) MASLD Activity Score (MAS) component grades and fibrosis staging, aiming to increase the reproducibility and scalability of pathologists' assessments and management of MASH cases. PathAI's AIM-MASH AI-based measurement tools have been utilized in over 20 presentations and publications, demonstrating their effectiveness in assisting pathologists with MASH CRN scoring in clinical trials. The addition of AIM-MASH broadens the set of tools available through AISight to assist pathologists in making reproducible and efficient assessments of MASH.

Source Statement

This curated news summary relied on this press release disributed by News Direct. Read the source press release here, PathAI Launches AI-Based Measurement of Metabolic Dysfunction-Associated Steatohepatitis (AIM-MASH) on AISight IMS

blockchain registration record for the source press release.